Ventures Vi Lpcmea Ventures... Net Worth

The estimated Net Worth of Ventures Vi Lpcmea Ventures... is at least $2.56 Milión dollars as of 18 September 2013. Ventures Ventures owns over 100,000 units of Tetraphase Pharmaceuticals stock worth over $1,041,906 and over the last 11 years Ventures sold TTPH stock worth over $1,515,114.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Ventures TTPH stock SEC Form 4 insiders trading

Ventures has made over 2 trades of the Tetraphase Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Ventures sold 100,000 units of TTPH stock worth $1,020,000 on 18 September 2013.

The largest trade Ventures's ever made was selling 100,000 units of Tetraphase Pharmaceuticals stock on 18 September 2013 worth over $1,020,000. On average, Ventures trades about 76,734 units every 1 days since 2013. As of 18 September 2013 Ventures still owns at least 47,992 units of Tetraphase Pharmaceuticals stock.

You can see the complete history of Ventures Ventures stock trades at the bottom of the page.

Insiders trading at Tetraphase Pharmaceuticals

Over the last 12 years, insiders at Tetraphase Pharmaceuticals have traded over $24,668,458 worth of Tetraphase Pharmaceuticals stock and bought 8,437,280 units worth $39,426,767 . The most active insiders traders include Capital, Llc Armistice Capi..., Llc Fmr a John Gordon Freund. On average, Tetraphase Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of $2,306,253. The most recent stock trade was executed by Jolla Pharmaceutical Co La on 28 July 2020, trading 3,737,360 units of TTPH stock currently worth $7,474,720.

What does Tetraphase Pharmaceuticals do?

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Complete history of Ventures Ventures stock trades at Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals executives and stock owners

Tetraphase Pharmaceuticals executives and other stock owners filed with the SEC include:

• Patrick Taylor Horn,
  Chief Medical Officer
• Garen G Bohlin,
  Director
• Jeffrey Chodakewitz,
  Director
• David Charles Lubner,
  SVP and CFO
• Nancy Wysenski,
  Director
• Jacques Dumas,
  Chief ScientificOfficer
• Geraldine Henwood,
  Director
• L Patrick Gage,
  Director
• John Craig Thompson,
  Chief Operating Officer
• Jolla Pharmaceutical Co La,
  10% owner
• Larry Tsai,
  Chief Medical Officer
• Kamalam Unninayar,
  Chief Financial Officer
• Larry G. Edwards,
  See Remarks
• Guy Macdonald,
  Director
• Steven R. Ph.D. Gullans,
  Director
• Llc Fmr,
  10% owner
• L. Patrick Jr. Giroir,
  Director
• Joaquim Trias,
  10% owner
• Joyce A. Sutcliffe,
  Senior Vice President, Biology
• Venture Partners Ii Lp Medi...,
  
• Xiao Yi Xiao,
  10% owner
• Ventures Vi Lpcmea Ventures...,
  
• Venture Partners Qualified ...,
  
• Ventures Fund 2004 L P Flag...,
  
• Venture Partners Qualified ...,
  
• Ventures Vi Lpcmea Ventures...,
  
• Medical Fund Lp Blume Frede...,
  
• Douglas G. Cole,
  Director
• John Gordon Freund,
  Director
• Maria D Stahl,
  See Remarks
• Christopher Watt,
  Senior Vice President, Finance
• Capital, Llc Armistice Capi...,